SEARCH

SEARCH BY CITATION

Keywords:

  • CD34;
  • cord blood;
  • ISHAGE;
  • single platform;
  • stem cells

Abstract

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. LITERATURE CITED

Single-platform flow cytometric absolute cell counting protocols provide increased robustness for CD34+ cell enumeration by limiting potential sources of imprecision. However, samples with any cellular fragmentation or debris, such as cord blood samples, provide challenges for these assays. We describe a simple, robust absolute CD34+ cell counting protocol, suitable for cord blood, using TRUCOUNT™ absolute count tubes (BD Biosciences, San Jose, CA) and a modified ISHAGE (International Society for Hematotherapy and Graft Engineering) gating strategy. An advantage of TRUCOUNT tubes is that each tube is supplied with a known number of lyophilized fluorescent beads. The method includes no-wash fixative-free ammonium chloride red blood cell lysis and the viability dye, 7-amino actinomycin D, to exclude dead cells. The threshold was set on CD45 expression in the FL1 channel and an exclusion gate in the forward scatter channel reduced debris. No manual adjustment of the gating regions was required, even for samples in less than optimal condition. Comparison of the TRUCOUNT-ISHAGE protocol with the original dual-platform ISHAGE assay (n = 30) and the single-platform ISHAGE protocol using Flow-Count™ Fluorospheres (Beckman Coulter, Fullerton, CA; n = 22) showed high correlation (R2 = 0.949 and 0.989, respectively) and no significant difference or bias for samples ranging from 22 to 600 CD34+ cells per microliter. Results are presented that demonstrate the detrimental effect of a fixative-containing lysis reagent when used in a lyse-and-wash procedure. The TRUCOUNT-ISHAGE protocol combines the attributes of TRUCOUNT tubes and the ISHAGE gating strategy to provide a single-platform protocol capable of achieving readily standardization of CD34+ cell enumeration. Cytometry (Comm. Clin. Cytometry) 46:254–261, 2001. © 2001 Wiley-Liss, Inc.

Human umbilical cord blood is a rich source of hematopoietic stem cells (HSC) that is being used increasingly as an alternative to bone marrow for HSC transplantation (1–3). The cellular content, in particular the number of HSC, is a principal factor in assessing the adequacy of cord blood units for clinical transplantation. HSC are contained within the CD34+ cell population, which represents typically less than 1% of the total leukocytes in cord blood (4). This places CD34 analysis in the category of “rare-event” analysis and has presented a challenge to the development of standardized, robust methods for the quantitation of HSC. Cord blood poses additional challenges. These include the presence of variable numbers of nucleated red blood cells (RBC; which can lead to overestimation of the leukocyte count) and the age of the samples, which is often greater than 24 h old. Increased apoptosis, cell death, and debris can potentially confound the analysis.

CD34+ cell enumeration has relied predominantly on flow cytometric procedures (5–7). Guidelines published by the International Society for Hematotherapy and Graft Engineering (ISHAGE; 8) were a significant attempt towards standardization of the CD34 assay. These guidelines were based on a dual-platform method whereby the percentage of CD34+ cells was determined by flow cytometry and the leukocyte count by an automated hematology analyzer. A lyse-and-wash method for sample preparation, a gating strategy based on a forward scatter threshold, CD45 staining to define the total leukocyte population, and light scatter characteristics were recommended. Nevertheless, the use of two instruments that were used to determine the absolute CD34+ cell number, the potential loss of cells during the lysis and wash steps, and the influence of the choice of lysis reagent were sources of variability and obstacles to standardization of the assay.

The development of single-platform methods enable the absolute CD34+ cell count to be determined by a single instrument. Most of these new methods rely on flow cytometry. An exception is a microvolume fluorometry method that utilizes a novel instrument, the IMAGN® 2000 with the STELLer™ CD34 assay kit (BD Biosciences, San Jose, CA). This instrument is fully automated. However, the STELLer CD34 assay has not been optimized for cord blood and samples in less than pristine conditions, such as cord blood samples greater than 24 h old, are problematic (Sparrow, unpublished observations). Furthermore, it cannot distinguish live from dead cells.

The flow cytometric-based single–platform methods center on the incorporation of a known number of fluorescent beads into the sample. Using a lyse-no-wash procedure for sample preparation enables the ratio of CD34+ cells to beads to be determined and the absolute CD34+ cell count to be calculated. The ProCOUNT™ assay (BD Biosciences) was the first commercial kit based on this approach. This three-color assay utilizes TRUCOUNT™ absolute count tubes (BD Biosciences), which contain a predispensed lyophilized pellet of a known number of 4.2-μm fluorescent beads. Due to the small beads, a forward scatter threshold cannot be used, necessitating the threshold to be set on a fluorescence channel. For the ProCOUNT assay, a proprietary nucleic acid dye is used to discriminate nucleated cells from erythrocytes, platelets, and debris and to set the threshold in the FL1 channel. CD34+ and CD45+ events are detected in the FL2 and FL3 channels, respectively. Acquisition and analysis are performed according to the gating strategy recommended by the manufacturer or by using proprietary software (BD Biosciences). Most evaluations of the ProCOUNT assay have been favorable (9, 10). However, significant discrepancies have been observed in some instances (11, 12). Furthermore, sample variability may necessitate manual adjustment of the gating regions, thus lessening the robustness of the assay. The assay has not been optimized for cord blood or bone marrow samples and, for single-laser flow cytometers, cannot be used to assess viability or analyze subpopulations.

Hübl et al. (13) described a modification of the ProCOUNT assay that is applicable to cord blood. In this modified protocol, the nucleic acid dye was replaced with a viability dye, YO-PRO-1 (FL1 channel), and the threshold was set on CD45 staining (FL3 channel). Nevertheless, manual adjustment of the regions was still required for each sample, potentially reducing the robustness of the assay.

Fornas et al. (14) described a no-lysis, no-wash whole blood method using TRUCOUNT tubes. The method relies on a vital nucleic acid dye, SYTO-13, to discriminate erythrocytes and debris from viable nucleated cells and to set the threshold in the FL1 channel. This protocol eliminates the lysis step. However, efflux of the SYTO-13 dye, particularly in P-glycoprotein–expressing cells, necessitated the addition of cyclosporin A to the assay mixture.

Using an alternative source of fluorescent beads, Keeney et al. (15) refined the original ISHAGE method by incorporating Flow-Count™ Fluorospheres (Beckman Coulter, Fullerton, CA), along with a no-wash, fixative-free lysis method for sample preparation and inclusion of a viability dye, 7-amino actinomycin D (7-AAD). This method formed the basis of the Stem-Kit™ CD34 HPC enumeration kit (Beckman Coulter). A significant advantage of this approach is the robustness and sensitivity of the ISHAGE gating strategy. However, Flow-Count Fluorospheres are supplied as a bead suspension that necessitates careful handling to ensure accuracy. Recent data from a multicenter trial conducted by the CD34 Task Force of the European Working Group of Clinical Cell Analysis demonstrated good interlaboratory agreement using the Flow-Count procedure (16). This trial was designed specifically to ensure a high level of standardization across the participating laboratories. Stabilized blood samples configured to represent mobilized peripheral blood stem cell specimens were used with a standardized protocol and targeted training. A protocol using TRUCOUNT tubes was also assessed and yielded comparable results with good interlaboratory agreement.

We describe an absolute cell counting procedure for CD34 analysis of cord blood using TRUCOUNT tubes and a modification of the ISHAGE gating strategy. The method includes fixative-free ammonium chloride RBC lysis and elimination of nonviable CD34+ cells using 7-AAD. The threshold is set on CD45 expression in the FL1 channel and debris is removed from the CD34 gating region using an exclusion gate in the forward scatter channel. This TRUCOUNT-based method compared favorably with the original dual-platform ISHAGE method and single-platform method using Flow-Count Fluorospheres. In addition, we show that the commercial lyse-and-fix reagent FACSLyse (BD Biosciences) has a detrimental effect on CD34+ cell enumeration when using a lyse-and-wash procedure. This new protocol combines the advantages of TRUCOUNT tubes and the ISHAGE gating strategy in a simple, robust assay.

MATERIALS AND METHODS

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. LITERATURE CITED

Cord Blood Specimens

Umbilical cord blood samples (n = 30) were collected from full-term deliveries with informed consent from the mothers and approval of the institutional ethics committee. Selection of this number of patients was based on a power analysis and sample size determination (using Statgraphics statistical software) that indicated that 16–30 samples was sufficient to compare the CD34 methods, with a 95% confidence level. All procedures used for collecting and processing cord blood were based on the standard operating procedures of the Australian Red Cross Blood Service-Victoria Cord Blood Bank. Briefly, cord blood was collected into a modified blood collection pack (Fenwal, Baxter Healthcare, Morelos, Mexico) containing 23 mL citrate-phosphate-dextrose-adenine anti-coagulant solution and processed within 36 h of collection. Cord blood was centrifuged to obtain the leukocyte-rich buffy coat layer. An aliquot of this cellular fraction was used for CD34+ cell analysis. All assays were performed immediately as samples became available. Blood cell counts were performed on either a Sysmex NE-8000 or Abbott Cell-Dyn 3200 hematology analyzer. Proportion of nucleated RBC was also determined by examining blood films.

CD34 Staining

Dual-platform ISHAGE protocol.

The original dual-platform ISHAGE protocol was performed as described previously (8). Cord blood samples were diluted in phosphate-buffered saline (PBS), pH 7.2, to obtain a leukocyte count of 10–20 × 109/L, as recommended by Keeney et al. (15). All samples were run in duplicate. Briefly, 100 μL of cord blood sample was incubated with 10 μL of FITC-conjugated anti-CD45 (clone HuLyM4; Silenus, Melbourne, Australia) and 20 μL of phycoerythrin (PE)-conjugated anti-CD34 (clone 581, Beckman Coulter) for 20 min at 4°C. Initial experiments included samples incubated with an isotype control PE-labeled IgG1 (Beckman Coulter) as a negative control for nonspecific binding. RBC were lysed with 2.0 mL of bicarbonate-buffered ammonium chloride solution (RBC lysis solution; 0.15 M NH4Cl, 0.01 M NaHCO3, 1.0 mM EDTA) for 15 min at room temperature. The cells were washed twice, resuspended in 1.0 mL PBS, stored on ice in the dark, and analyzed within 1 h.

For some experiments, RBC were lysed for 10 min using a fixative-containing RBC lysis reagent FACSLyse (BD Biosciences), washed twice, and resuspended in PBS.

Single-platform protocol using TRUCOUNT tubes.

CD34 and CD45 antigen staining was performed as described above, except TRUCOUNT tubes (BD Biosciences) were used. The tubes contain a known number of lyophilized 4.2-μm fluorescent beads. Immediately after the addition of 2.0 mL of RBC lysis solution, 4 μL of 0.5 mg/mL 7-AAD in methanol (Molecular Probes, Eugene, OR) was added. To ensure accuracy, reverse pipetting was used to dispense volumes greater than 20 μL. The tubes were incubated at room temperature for 15 min, then placed on ice in the dark and analyzed within 1 h. Samples were mixed gently immediately prior to analysis.

Single-platform protocol using Flow-Count Fluorospheres.

Antigen staining and RBC lysis/7-AAD treatment were performed as described above, except plain tubes were used (Falcon, BD Biosciences). Following lysis treatment, 100 μL of Flow-Count Fluorospheres (Beckman Coulter) was added by reverse pipetting. These beads are supplied as a suspension of a defined concentration of 10-μm fluorescent beads in an aqueous medium containing surfactant and 1% formaldehyde. The beads must be well mixed and equilibrated to room temperature prior to use. Following addition of the beads, the sample was mixed gently and analyzed immediately.

Flow Cytometry

Samples were analyzed on a FACScan flow cytometer (BD Biosciences) with a 488-nm argon laser and Cell Quest 3.1 software (BD Biosciences). The instrument was aligned and calibrated daily using a three-color mixture of CaliBRITE beads (BD Biosciences) with FACSComp software (BD Biosciences).

Gating strategy: dual-platform ISHAGE protocol.

The original dual-platform ISHAGE gating strategy and calculation to obtain the number of CD34+ cells per microliter was exactly as described previously (8).

Gating strategy: single-platform TRUCOUNT-ISHAGE protocol.

Figure 1 shows the gating strategy for CD34 analysis using TRUCOUNT tubes. This protocol followed closely that of Keeney et al. (15) for single-platform ISHAGE analysis using Flow-Count Fluorospheres, with the following modifications. Because TRUCOUNT beads produce a very low forward scatter signal, a forward scatter threshold cannot be used. Instead, an exclusion gate (Fig. 1, Plot 9) was drawn to simulate a forward scatter threshold and eliminate signals arising from debris, while allowing collection of all the bead data. An FL1 threshold was set on CD45 expression, with care to ensure that CD45low/CD34+ cells were not excluded from analysis (Fig. 1, Plot 1). The live leukocytes were identified as 7-AAD–negative events (Fig. 1, Plot 2). The gating out of dead cells (region R7) also served to gate out the TRUCOUNT beads from further CD34+ cell analysis. The TRUCOUNT beads, evident as a population of bright events in each fluorescence channel, were enumerated in region R6 (Fig. 1, Plot 8). To exclude nonbead events, R6 was drawn tightly around the beads in line with the manufacturer's instructions. CD34+ events were enumerated in G4 (Fig. 1, Plot 6). A total of 100,000 viable leukocytes (G1) were collected, or a minimum of 100 CD34+ events and 2,000 bead events. The number of CD34+ cells per microliter was calculated by the following formula:

  • equation image
Gating strategy: Flow-Count–ISHAGE protocol.

The gating strategy described by Keeney et al. (15) was used with the modification that the bead data were collected by forward scatter versus time parameters. The number of CD34+ cells per microliter was calculated as described previously (15).

Statistical Analysis

Comparison of the number of CD34+ cells obtained by the different methods was determined by the nonparametric Wilcoxon test for paired samples and by Pearson's correlation coefficient, using Minitab software (Minitab, State College, PA). Significance was defined as P < 0.05. Linear regression analysis was performed using Excel 97 software (Microsoft, Redmond, WA). Agreement between the methods was assessed by analysis of the relationship between the differences and the mean of the differences, as recommended by Bland and Altman (17). Close agreement is indicated by the mean of the differences approximating zero and the scatter of the data points being randomly distributed around the mean of the differences.

thumbnail image

Figure 1. Modified ISHAGE gating strategy using TRUCOUNT tubes with FITC-anti-CD45, PE-anti-CD34, and 7-AAD on cord blood. Listmode data were acquired on a FACScan (BD Biosciences) and analyzed with Cell Quest software. Plot 1: Threshold on FL-1 channel; all events collected are shown in this ungated plot. Plot 2: Discrimination of live cells from dead cells. Events falling in R7 are gated out of further analysis. Plot 3: First ISHAGE plot, gated on live cells. R1 defines all CD45+ leukocytes and R5 defines the lymphocyte population. Plot 4: Second ISHAGE plot, gated on live CD45+ leukocytes. R2 defines possible CD34+ cells. Plot 5: Third ISHAGE plot, gated on live CD45+CD34+ events. R3 defines clustering of CD34+ events. Plot 6: Fourth ISHAGE plot, gated on live CD45+CD34+ events. R4 defines clustering CD34+ events which have similar light scatter properties and is used to enumerate CD34+ cells. Plot 7: Live lymphocytes. The left side of R4 is drawn to include cells no smaller than a small lymphocyte, and assists to position the exclusion gate in Plot 9. Plot 8: R6 defines TRUCOUNT beads; this plot assists to define the lower limit of CD45 expression of CD34+ cells. Plot 9: Scatter plot. R8 defines an exclusion gate, which removes most of the platelets and debris while allowing TRUCOUNT beads to be collected.

Download figure to PowerPoint

RESULTS

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. LITERATURE CITED

Influence of RBC Lysis Reagent

Our original method for CD34+ cell analysis was based on the dual-platform ISHAGE protocol and included lysis of RBC with a proprietary fixative-containing lysis reagent, FACSLyse (BD Biosciences), followed by two washes (8). Initial experiments were performed to compare FACSLyse with a nonfixative-containing ammonium chloride RBC lysis solution. The results from cord blood samples (n = 10), each prepared simultaneously using the two lysing reagents and analyzed by the dual-platform ISHAGE protocol, showed that the FACSLyse method gave significantly lower (P < 0.006) estimates of CD34+ cell number than the ammonium chloride method (median CD34+ cells per microliter with FACSLyse = 95, 95% confidence interval [CI] 51–247; median CD34+ cells per microliter with ammonium chloride = 172, CI 93–375). Although a high correlation coefficient was achieved (R2 = 0.942), the slope was 0.65 and intercept –11.2 (Fig. 2A). Analysis of the differences of the means of the two methods, as described by Bland and Altman (17), gave a mean bias of 85.1 (Fig 3A), indicating significant disagreement between the methods. We also analyzed mobilized peripheral blood samples supplied for an interlaboratory CD34 assessment program (18). Comparison with results from other laboratories indicated closer agreement with the fixative-free ammonium chloride method and underestimation using FACSLyse (results not shown). All subsequent experiments used the ammonium chloride RBC lysis reagent.

thumbnail image

Figure 2. Comparison of methods. A: Dual-platform ISHAGE with FACSLyse versus dual-platform ISHAGE with ammonium chloride lysis reagent. B: Single-platform TRUCOUNT versus dual-platform ISHAGE with ammonium chloride lysis reagent. C: Single-platform Flow-Count versus dual-platform ISHAGE with ammonium chloride lysis reagent. D: Single-platform TRUCOUNT versus single-platform Flow-Count. Dashed line represents theoretical perfect agreement between the methods. Solid line represents calculated linear regression line of the observed data. Regression equation for the observed data is shown.

Download figure to PowerPoint

thumbnail image

Figure 3. Bland-Altman plots of differences between the methods versus their mean. A: Dual-platform ISHAGE with ammonium chloride versus dual-platform ISHAGE with FACSLyse. B: Single-platform TRUCOUNT versus dual-platform ISHAGE with ammonium chloride. C: Single-platform Flow-Count versus dual-platform ISHAGE with ammonium chloride. D: Single-platform TRUCOUNT versus single-platform Flow-Count. Solid line represents the mean of the differences or bias. Dashed lines represent mean of the difference (bias) ± 2 SD. A mean bias equal to zero represents perfect agreement.

Download figure to PowerPoint

Single-Platform TRUCOUNT-ISHAGE Protocol

The original ISHAGE gating strategy was modified to include a polygonal exclusion gate in the forward scatter channel and the threshold was set on CD45+ events in the FL1 channel. Acquisition time to acquire 100,000 live CD45+ events was typically 5 to 6 min and the entire assay could be completed in less than 1 h. The cord blood samples analyzed had a range of 22–600 CD34+ cells per microliter and the mean coefficient of variation of replicate samples was 7% (range 0–15 %). A negative control was included in initial experiments but was not necessary, as has been shown for the ISHAGE protocol (8, 15). No manual adjustment of the gating regions was required for any of the samples.

Comparison of CD34 Protocols

Figure 2B shows the linear correlation of the absolute CD34+ cell counts of cord blood samples (n = 30) analyzed simultaneously by the single-platform TRUCOUNT-ISHAGE protocol and the dual-platform ISHAGE protocol. The two methods showed good correlation (R2 = 0.949, slope 0.97, and intercept 5.0) and good agreement, as demonstrated by a mean bias of 0.11 (Fig. 3B). There was no significant difference between the median CD34+ cells per microliter obtained for the two methods (TRUCOUNT median = 152, CI 110–220; dual-platform ISHAGE median = 155, CI 111–219; P = 0.86).

Similarly, comparison of the single-platform method using Flow-Count Fluorospheres and the dual-platform ISHAGE protocol (n = 22) showed good correlation (R2 = 0.954, slope 0.89, and intercept 19.4; Fig. 2C). There was good agreement between the methods as determined by a mean bias of 1.2 (Fig. 3C). The median CD34+ cells per microliter values were not significantly different (Flow-Count median = 160, CI 107–234; dual-platform ISHAGE median = 155, CI 104–222; P = 0.66).

Finally, the single-platformTRUCOUNT and Flow-Count methods were compared. The results (n = 22) showed good correlation (R2 = 0.989, slope 1.0, and intercept -9.2; Fig. 2D) and good agreement between the methods as determined by a mean bias of -5.7 (Fig. 3D). The median CD34+ cells per microliter values were comparable (TRUCOUNT median = 150, CI 102–217; Flow-Count median = 160, CI 107–234).

DISCUSSION

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. LITERATURE CITED

The increasing clinical utilization of HSC transplantation, the establishment of cord blood banks, and the inclusion of HSC processing facilities within the control of national regulatory authorities have hastened the need for accurate and robust assays for CD34+ cell enumeration. Cord blood has posed additional challenges, particularly due to the presence of varying numbers of nucleated RBC and the extended age of the samples at the time of CD34+ cell enumeration. Single-platform absolute CD34+ cell-counting protocols offer the greatest potential for the development of robust assays capable of analytical accuracy and standardization. In this study, we described a modification of the single-platform ISHAGE protocol that incorporates an alternative source of fluorescent beads, presented in the format of TRUCOUNT tubes, which is suitable for analysis of cord blood samples.

Initial experiments were performed to ascertain the influence of the RBC lysis reagent. These experiments utilized the original dual-platform ISHAGE lyse-and-wash protocol. Our results demonstrated that the fixative-containing FACSlyse reagent gave significantly lower estimates of the CD34+ cell number compared with the fixative-free bicarbonate-buffered ammonium chloride RBC lysis solution. These results were consistent with those reported by others (19–24). Loss of CD34+ cells following treatment with fixative-containing solutions has been suggested to be a consequence of increased stickiness of fixed cells (24). Fixed cells may be lost from the cell suspension either by increased adhesion to the surface of the assay tubes or greater loss during washing. Gratama et al. (24) recommended that the wash steps be omitted to minimize cell loss associated with fixative-containing RBC lysis reagents.

Other investigators have cautioned the use of ammonium chloride RBC lysis reagents due to the observation that CD34+ cells undergo light scatter changes characteristic of apoptosis when exposed to such reagents (21). In the experiments described here, sample analysis was completed typically within 30 min following the addition of the ammonium chloride lysis solution. If the samples were not analyzed immediately, they were placed on ice following the 15-min lysis step. In some instances, samples were analyzed up to 60 min following the addition of lysis solution (results not shown). No change in the light scatter characteristics was observed with delayed sample analysis, seemingly a benefit of placing the tubes on ice prior to analysis (23). Based on these results, we adopted a fixative-free bicarbonate-buffered ammonium chloride solution as the preferred RBC lysis reagent.

In order to have in place a more robust CD34 assay for routine analysis of HSC products, in particular cord blood, we investigated the options of single-platform flow cytometry protocols. We preferred a method that utilized the ISHAGE gating strategy because of its robustness, sensitivity, and widespread use. Although the single-platform ISHAGE method using Flow-Count Fluorospheres is well established (15), there are disadvantages with the use of Flow-Count or with similar fluorescent bead suspensions. These include (1) ensuring a homogenous bead suspension prior to dispensing; (2) precise pipetting of the fluorospheres, as well as the sample; (3) presence of preservative in the bead suspension, which can have an adverse effect on cell viability (25), necessitating that the beads be added immediately prior to flow cytometric analysis; and (4) comparing the practicality of pack size versus cost-effectiveness (i.e., the current 200-test pack size of Flow-Count Fluorospheres combined with a 1-month expiry upon opening may not be cost-effective for many laboratories).

We were attracted to using TRUCOUNT tubes, as this approach eliminates a potential source of error associated with dispensing the beads. This product is ready to use, does not contain preservatives that interfere with cell viability, and each 25-test pack has a 2-month expiry upon opening. We modified the ISHAGE protocol by performing CD34 and CD45 labeling, RBC lysis, and 7-AAD staining in the TRUCOUNT tubes. Because the TRUCOUNT beads were small, modifications were required to the single-platform ISHAGE gating strategy compared with those described previously (15). Unlike Flow-Count Fluorospheres, a forward scatter threshold cannot be used for TRUCOUNT beads. Consequently, the threshold must be set on a fluorescence channel that defines the denominator cell population. We chose CD45 expression in the FL1 channel to set the threshold, allowing the FL3 channel to be used for the viability dye, 7-AAD. In order to reduce debris in the acquisition region, a polygonal exclusion gate was set in the forward scatter channel between the bead events and cells. The results obtained from cord blood samples, which had a wide range of CD34+ cell concentrations, showed good agreement compared with the original dual-platform ISHAGE protocol and the single-platform Flow-Count–ISHAGE protocol. We found this TRUCOUNT-ISHAGE method to be technically simple and time efficient. As has been noted by others (5, 6), particular care must be taken in dispensing the sample and RBC lysis reagent to ensure accuracy and reproducibility of the results. Reverse pipetting using calibrated pipettes is essential. Coefficients of variation of less than 10% were readily achievable. The TRUCOUNT-ISHAGE gating strategy described proved to be robust and efficient. Data acquisition was achieved within 5–6 min per sample and no manual adjustment of the gating regions was required, even for samples that were in less than pristine condition.

We also assessed the TRUCOUNT-ISHAGE protocol for the enumeration of CD34+ cells in mobilized peripheral blood and leukapheresis samples. The results obtained were comparable with those achieved using the dual-platform ISHAGE protocol (results not shown), indicating that this method is applicable for samples other than cord blood. We did not observe the “vanishing counting bead” phenomenon (26) in our small series of leukapheresis samples. However, the recommendation of ensuring sufficient protein in diluting media is notable.

In conclusion, we described a protocol that combines the attributes of TRUCOUNT tubes and the ISHAGE gating strategy to provide a robust, accurate single-platform absolute viable CD34+ cell-counting method. Although we established this assay for cord blood samples, this protocol would be equally applicable to other types of HSC samples as indicated by our preliminary results with mobilized peripheral blood and leukapheresis samples. This TRUCOUNT-ISHAGE protocol provides an alternative robust, time-efficient assay that is capable of readily achieving standardization across clinical laboratories.

Acknowledgements

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. LITERATURE CITED

We thank Dr. Jenny Cauchi (Douglas Hocking Research Institute, Geelong) and Lanny Ramadi for assistance in preparing the samples. We thank Robert Sutherland (Oncology Research, The Toronto Hospital, Toronto, Canada) for his generous and helpful suggestions regarding flow cytometry gating strategies.

LITERATURE CITED

  1. Top of page
  2. Abstract
  3. MATERIALS AND METHODS
  4. RESULTS
  5. DISCUSSION
  6. Acknowledgements
  7. LITERATURE CITED
  • 1
    Cairo MS, Wagner JE. Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood 1997; 90: 46654678.
  • 2
    Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, Berkowitz RL, Cabbad M, Dobrila NL, Taylor PE, Rosenfield RE, Stevens CE. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 15651577.
  • 3
    Gluckman E. Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol 2000; 28: 11971205.
  • 4
    Sutherland DR, Keating A, Nayar R, Anania S, Stewart AK. Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. Exp Hematol 1994; 22: 10031010.
  • 5
    Gratama JW, Orfao A, Barnett D, Brando B, Huber A, Janossy G, Johnsen HE, Keeney M, Marti GE, Preijers F, Rothe G, Serke S, Sutherland DR, Van Der Schoot CE, Schmitz G, Papa S. Flow cytometric enumeration of CD34+ hematopietic stem and progenitor cells. Cytometry 1998; 34: 128142.
  • 6
    Brando B, Barnett D, Janossy G, Mandy F, Autran B, Rothe G, Scarpati B, D'Avanzo G, D'Hautcourt J-L, Lenkei R, Schmitz G, Kunkl A, Chianese R, Papa S, Gratama JW. Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. Cytometry 2000; 42: 327346.
  • 7
    Keeney M, Sutherland DR. Stem cell enumeration by flow cytometry: current concepts and recent developments in CD34+ cell enumeration. Cytotherapy 2000; 2: 395402.
  • 8
    Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996; 5: 213226.
  • 9
    McNiece I, Kern B, Zilm K, Brunaud C, Dziem G, Briddell R. Minimization of CD34+ cell enumeration variability using the ProCOUNT standardized methodology. J Hematother 1998; 7: 499504.
  • 10
    Sims LC, Brecher ME, Gertis K, Jenkins A, Nickischer D, Schmitz JL, Sparks S, Wright P, Bentley S. Enumeration of CD34-positive stem cells: evaluation and comparison of three methods. J Hematother 1997; 6: 213226.
  • 11
    Gutensohn K, Carrero I, Krueger W, Kroeger N, Schäfer P, Luedemann K, Kuehnl P. Semi-automated flow cytometric analysis of CD34-expressing hematopoietic cells in peripheral blood progenitor cell apheresis products. Transfusion 1999; 39: 12201226.
  • 12
    Barbosa IL, Sousa ME, Godinho MI, Carvalhais A. Single- versus dual-platform assays for human CD34+ cell enumeration. Cytometry 1999; 38: 274279.
  • 13
    Hübl W, Iturraspe J, Martinez GA, Hutcheson CE, Roberts CG, Fisk DD, Sugrue MW, Wingard JR, Braylan RC. Measurement of absolute concentration and viability of CD34+ cells in cord blood and cord blood products using fluorescent beads and cyanine nucleic acid dyes. Cytometry 1998; 34: 121127.
  • 14
    Fornas O, Garcia J, Petriz J. Flow cytometry of CD34+ cells in whole blood. Nature Med 2000; 6: 833836.
  • 15
    Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. Cytometry 1998; 34: 6170.
  • 16
    Barnett D, Granger V, Kraan J, Whitby L, Reilly JT, Papa S, Gratama JW. Reduction of intra- and interlaboratory variation in CD34+ stem cell enumeration using a stable test material, standard protocols and targeted training. Br J Haematol 2000; 108: 784792.
  • 17
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307310.
  • 18
    Chang A, Ma DDF. The influence of flow cytometric gating strategy on the standardization of CD34+ cell quantitation: an Australian multicenter study. J Hematother 1996; 5: 605616.
  • 19
    Bossuyt X, Marti GE, Fleisher TA. Comparative analysis of whole blood lysis methods for flow cytometry. Cytometry 1997; 30: 124133.
  • 20
    Cassens U, Gutensohn K, Garritsen H, Kelsch R, Kuehnl P, Sibrowski W. The influence of different erythrocyte lysing procedures on flow cytometric determination of CD34+ cells in umbilical cord blood transplants. Transfusion Med 1998; 8: 111118.
  • 21
    Serke S, van Lessen A, Pardo I, Huhn D. Selective susceptibility of CD34-expressing cells to acquire flow cytometric features of apoptosis/necrosis on exposure to an ammonium chloride-based red blood cell lysing reagent. J Hematother 1998; 7: 315318.
  • 22
    Menéndez P, Redondo O, Rodriguez A, Lopez-Berges MC, Ercilla G, López A, Durán A, Almeida J, Pérez-Simón JA, San Miguel JF, Gratama JW, Orfao A. Comparison between a lyse-and-then-wash method and a lyse-non-wash technique for the enumeration of CD34+ hematopoietic progenitor cells. Cytometry 1998; 34: 264271.
  • 23
    Keeney M, Chin-Yee I, Nayar R, Sutherland DR. Effect of fixatives on CD34+ cell enumeration. J Hematother Stem Cell Res 1999; 8: 327329.
  • 24
    Gratama JW, Menéndez P, Kraan J, Orfao A. Loss of CD34+ hematopoietic progenitor cells due to washing can be reduced by the use of fixative-free erythrocyte lysing reagents. J Immunol Methods 2000; 239: 1323.
  • 25
    Mifsud NA, Wall DM, Sparrow RL. An automated cell counter compared with flow cytometry for obtaining accurate leukocyte and lymphocyte subset estimations. Transfusion Med 1998; 8: 157.
  • 26
    Brando B, Göhde W Jr, Scarpati B, D'Avanzo G. The “vanishing counting bead” phenomenon: effect on absolute CD34+ cell counting in phosphate-buffered saline-diluted leukapheresis samples. Cytometry 2001; 43: 154160.